A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

NCT04764487 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

178

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma Metastatic

Interventions

DEVICE: KidneyPRO
OTHER: standard follow-up

Sponsor

Weprom

Collaborators

[object Object]
[object Object]